医学
养生
卡铂
膀胱癌
内科学
泌尿科
化疗
长春碱
阶段(地层学)
顺铂
肿瘤科
膀胱切除术
外科
胃肠病学
癌症
古生物学
生物
作者
Joaquim Bellmunt,Antoni Ribas,Joan Albanell,Begoña Bermejo,Ruth Vera,Javier Torres,J. Morote,M. A. Lopez-Pacios,J.M. Banús,Á. Rovirosa,Joan Carulla,L.A. Solé
标识
DOI:10.1097/00000421-199608000-00004
摘要
Carboplatin, methotrexate, and vinblastine (M-CAVI) is an active and well-tolerated regimen for bladder cancer patients ineligible for cisplatin-based regimens. We treated 47 T2-4 N0 M0 bladder cancer patients with M-CAVI in a neoadjuvant phase II trial. These 47 patients are evaluable for clinical response and toxicity. Clinical overall response rate was 34%, for a 95% confidence interval (CI95%) of 21-49%. Pathological response was seen in 40% of the patients (CI95%, 26-56%) with a 26.5% rate of pathological complete response (CI95%, 15-42%). Factors associated with the achievement of a response to therapy were the initial TNM stage (pT3a or lower, greater than pT3a, p = 0.001) and a Karnofsky score greater or equal than 90%, which was marginally significant (p = 0.08). With a median follow-up of 14 months, the disease-specific actuarial survival at 2 years is 42%. No patients has relapsed beyond 21 months of follow-up in a disease-free status. Toxic effects have been moderate. In conclusion, M-CAVI is an active and well-tolerated regimen that should be compared in terms of response rate and survival with a cisplatin-based regimen for invasive bladder cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI